First Trust Nasdaq Pharmaceuticals ETF (FTXH)
25.68
+0.12
(+0.47%)
USD |
NASDAQ |
Jun 01, 16:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.60% | -0.23% | 30.74M | 9667.87 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 1.38% | 77.00% | 11.77M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals IndexTM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | First Trust |
| Prospectus Benchmark Index | |
| Nasdaq US Smart Pharmaceuticals TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Chris Peterson | 6.61 yrs |
| Daniel Lindquist | 6.61 yrs |
| David McGarel | 6.61 yrs |
| Jon Erickson | 6.61 yrs |
| Roger Testin | 6.61 yrs |
| Stan Ueland | 6.61 yrs |
| Erik Russo | 2.33 yrs |
Performance Versus Category
As of May 31, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of June 01, 2023.
Basic Info
| Investment Strategy | |
| The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals IndexTM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | First Trust |
| Prospectus Benchmark Index | |
| Nasdaq US Smart Pharmaceuticals TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Chris Peterson | 6.61 yrs |
| Daniel Lindquist | 6.61 yrs |
| David McGarel | 6.61 yrs |
| Jon Erickson | 6.61 yrs |
| Roger Testin | 6.61 yrs |
| Stan Ueland | 6.61 yrs |
| Erik Russo | 2.33 yrs |